Journal Mobile Options
Table of Contents
Vol. 36, No. 3, 2012
Issue release date: September 2012
Am J Nephrol 2012;36:287–295
(DOI:10.1159/000342207)

The Impact of Chronic Obstructive Pulmonary Disease and Smoking on Mortality and Kidney Transplantation in End-Stage Kidney Disease

Kent B.D. · Eltayeb E.E. · Woodman A. · Mutwali A. · Nguyen H.T. · Stack A.G.
aRegional Kidney Centre, Letterkenny General Hospital, Health Services Executive-West, Donegal, bPulmonary and Sleep Disorders Unit, St. Vincent’s University Hospital, Dublin, cDepartment of Medicine, University Hospital Limerick, and dGraduate Entry Medical School, University of Limerick, Limerick, Ireland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Chronic obstructive pulmonary disease (COPD) and tobacco use are leading causes of morbidity and mortality. The prevalence and clinical impact of COPD on mortality and kidney transplantation among patients who begin dialysis therapy is unclear. Methods: We explored the clinical impact of COPD and continued tobacco use on overall mortality and kidney transplantation in a national cohort study of US dialysis patients. National data on all dialysis patients (n = 769,984), incident between May 1995 and December 2004 and followed until October 31, 2006, were analyzed from the United States Renal Data System. Prevalence and period trends were determined while multivariable Cox regression evaluated relative hazard ratios (RR) for death and kidney transplantation. Results: The prevalence of COPD was 7.5% overall and increased from 6.7 to 8.1% from 1995–2004. COPD correlated significantly with older age, cardiovascular conditions, cancer, malnutrition, poor functional status, and tobacco use. Adjusted mortality risks were significantly higher for patients with COPD (RR = 1.20, 95% CI 1.18–1.21), especially among current smokers (RR = 1.28, 95% CI 1.25–1.32), and varied inversely with advancing age. In contrast, the adjusted risks of kidney transplantation were significantly lower for patients with COPD (RR = 0.47, 95% CI 0.41–0.54, for smokers and RR = 0.54, 95% CI 0.50–0.58, for non-smokers) than without COPD [RR = 0.72, 95% CI 0.70–0.75, for smokers and RR = 1.00 for non-smokers (referent category)]. Conclusions: Patients with COPD who begin dialysis therapy in the US experience higher mortality and lower rates of kidney transplantation, outcomes that are far worse among current smokers.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.
  2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–555.
  3. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V: Chronic renal failure: a neglected comorbidity of COPD. Chest 2010;137:831–837.
  4. USRDS System: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, Bethesda, MD, 2009.
  5. Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001;12:1516–1523.
  6. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998;31:997–1006.
  7. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG: Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003;14:415–424.
  8. Wagner M, Ansell D, Kent DM, Griffith JL, Naimark D, Wanner C, Tangri N: Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis 2011;57:894–902.
  9. Chapter IV. Patient characteristics at the start of ESRD: data from the HCFA medical evidence form. Am J Kidney Dis 1999;34(2 suppl 1):S63–S73.
  10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
  11. Almagro P, Salvado M, Garcia-Vidal C, Rodriguez-Carballeira M, Delgado M, Barreiro B, Heredia JL, Soriano JB: Recent improvement in long-term survival after a COPD hospitalisation. Thorax 2010;65:298–302.

    External Resources

  12. Han MK, Postma D, Mannino DM, Giardino ND, Buist S, Curtis JL, Martinez FJ: Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med 2007;176:1179–1184.

    External Resources

  13. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, Pride NB: Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789–794.
  14. Sin DD, Man SF: Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8–11.
  15. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA: Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091–1097.

    External Resources

  16. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS: Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004;65:2380–2389.
  17. Stack AG, Murthy BV: Cigarette use and cardiovascular risk in chronic kidney disease: an unappreciated modifiable lifestyle risk factor. Semin Dial 2010;23:298–305.

    External Resources

  18. Liebman SE, Lamontagne SP, Huang LS, Messing S, Bushinsky DA: Smoking in dialysis patients: a systematic review and meta-analysis of mortality and cardiovascular morbidity. Am J Kidney Dis 2011;58:257–265.

    External Resources

  19. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23–28.
  20. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250–255.
  21. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627–636.
  22. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W: Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290:353–359.
  23. Aparicio M, Cano N, Chauveau P, Azar R, Canaud B, Flory A, Laville M, Leverve X: Nutritional status of haemodialysis patients: a French national cooperative study. French Study Group for Nutrition in Dialysis. Nephrol Dial Transplant 1999;14:1679–1686.
  24. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000;11:520–529.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50